{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=27", "query": { "intervention": "capecitabine", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T15:27:38.403Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02079220", "title": "A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Arm A", "type": "DRUG" }, { "name": "Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James J Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-03", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2017-07-31", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02079220" }, { "nct_id": "NCT00019773", "title": "Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma of the Appendix", "Colorectal Cancer", "Small Intestine Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019773" }, { "nct_id": "NCT05247905", "title": "Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Neuroendocrine Tumor", "Unresectable Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-02-16", "completion_date": "2033-04-01", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 171, "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Emeryville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05247905" }, { "nct_id": "NCT01821729", "title": "Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Proton Beam Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2013-08-16", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821729" }, { "nct_id": "NCT07700979", "title": "Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric / Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Cadonilimab", "type": "DRUG" }, { "name": "CAPOX regimen", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akeso", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2026-09-24", "completion_date": "2030-08-18", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700979" }, { "nct_id": "NCT06648785", "title": "Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GI Cancers" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "Fluoropyrimidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-10-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 2, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT06648785" }, { "nct_id": "NCT01280643", "title": "Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "nucleic acid sequencing", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "DNA analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "GENETIC", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2010-03", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2021-03-15", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01280643" }, { "nct_id": "NCT05249426", "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "BI 765063", "type": "DRUG" }, { "name": "Ezabenlimab", "type": "DRUG" }, { "name": "BI 836880", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Investigator´s Choice Chemotherapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-04-12", "completion_date": "2026-06-22", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05249426" }, { "nct_id": "NCT00977119", "title": "Investigation of Genetic Determinants of Capecitabine Toxicity", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Side-effect questionnaires", "type": "OTHER" }, { "name": "research blood samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 240, "start_date": "2009-11-23", "completion_date": "2021-06-21", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00977119" }, { "nct_id": "NCT00033540", "title": "S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2003-09", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2017-09-12", "last_synced_at": "2026-10-28T15:27:38.403Z", "location_count": 112, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 79 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Fairfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033540" } ] }